Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

IDEAYA Aktie

 >IDEAYA Aktienkurs 
23.2 EUR    +4.5%    (Tradegate)
Ask: 23.2 EUR / 128 Stück
Bid: 23 EUR / 130 Stück
Tagesumsatz: 845 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IDEAYA Aktie über LYNX handeln
>IDEAYA Performance
1 Woche: +12,6%
1 Monat: +11,0%
3 Monate: +25,7%
6 Monate: +31,8%
1 Jahr: -31,2%
laufendes Jahr: -3,7%
>IDEAYA Aktie
Name:  IDEAYA BIOSCIENCE DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45166A1025 / A2PJPB
Symbol/ Ticker:  30J (Frankfurt) / IDYA (NASDAQ)
Kürzel:  FRA:30J, ETR:30J, 30J:GR, NASDAQ:IDYA
Index:  -
Webseite:  https://www.ideayabio.com..
Profil:  Ideaya Biosciences Inc. is a biotechnology company..
>Volltext..
Marktkapitalisierung:  2031.63 Mio. EUR
Unternehmenswert:  1488.87 Mio. EUR
Umsatz:  5.97 Mio. EUR
EBITDA:  -324.5 Mio. EUR
Nettogewinn:  -283.19 Mio. EUR
Gewinn je Aktie:  -3.23 EUR
Schulden:  22.7 Mio. EUR
Liquide Mittel:  97.85 Mio. EUR
Operativer Cashflow:  -250.67 Mio. EUR
Bargeldquote:  12.1
Umsatzwachstum:  -46.79%
Gewinnwachstum:  -96.24%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  IDEAYA
Letzte Datenerhebung:  07.09.25
>IDEAYA Kennzahlen
Aktien/ Unternehmen:
Aktien: 87.64 Mio. St.
Frei handelbar: 92%
Rückkaufquote: -13.3%
Mitarbeiter: 131
Umsatz/Mitarb.: 0.05 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 72.24%
Bewertung:
KGV: -
KGV lG: -
KUV: 323.88
KBV: 2.47
PEG-Ratio: -0.09
EV/EBITDA: -
Rentabilität:
Bruttomarge: 42.56%
Gewinnmarge: -4740.03%
Operative Marge: -5488.94%
Managementeffizenz:
Gesamtkaprendite: -32.93%
Eigenkaprendite: -35.09%
>IDEAYA Peer Group

Es sind 601 Aktien bekannt.
 
07.09.25 - 18:06
 IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer (PR Newswire)
 
80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg expansion dose of IDE849 77.1% (27/35) ORR and 60.0% (21/35) confirmed ORR (4 pending......
04.09.25 - 16:30
 Ideaya Biosciences gets coverage initiation at Barclays and Citizens (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.09.25 - 12:03
 IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of......
03.09.25 - 12:02
 IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors (PR Newswire)
 
Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025 Preclinical profile of IDE892 and mechanistic combination rationale with IDE397, IDEAYA's proprietary MAT2A inhibitor, will be presented at the 10-Year Anniversary R&D Day on September 8th SOUTH SAN......
02.09.25 - 16:00
 IDEAYA Biosciences and Servier in-pact to develop eye cancer treatment (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.09.25 - 12:01
 Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide (PR Newswire)
 
Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US Darovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical need IDEAYA will......
29.08.25 - 20:03
 IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the company's single-arm, Phase 1/2 trial of darovasertib in combination with crizotinib in......
29.08.25 - 12:03
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 28, 2025, the Compensation Committee of IDEAYA's......
25.08.25 - 12:03
 IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Cantor......
18.08.25 - 12:03
 IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025 (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its in-person R&D Day in conjunction with the......
05.08.25 - 23:00
 IDEAYA (IDYA) Q2 Net Loss Improves 27% (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.25 - 12:18
 IDEAYA Biosciences GAAP EPS of -$0.88 misses by $0.08 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.25 - 12:03
 IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
 
Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track to report median PFS data by year-end 2025; potential to enable a U.S. accelerated approval filing First-reported median overall survival data in over 40 1L MUM......
01.08.25 - 12:01
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Aug. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 31, 2025, the Compensation Committee of IDEAYA's......
24.07.25 - 15:27
 IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma (PR Newswire)
 
The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohorts Darovasertib has received U.S. FDA Breakthrough Therapy Designation for use in neoadjuvant uveal melanoma for subjects requiring enucleation Initiated a multi-site,......
23.07.25 - 12:03
 IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., July 23, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it will host an in-person and virtual R&D Day on September 8, 2025 from......
22.07.25 - 19:03
 IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC (PR Newswire)
 
Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial Data will include patients from the dose escalation and at multiple expansion doses U.S. Phase 1 trial of IDE849 in SCLC......
21.07.25 - 12:03
 IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event. 2025 BTIG......
27.06.25 - 12:01
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., June 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 26, 2025, the Compensation Committee of IDEAYA's......
02.06.25 - 12:03
 IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., June 2, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. 2025......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Mittelmaß . . . Die übliche Ballungszone des menschlichen Geistes. - Julio Cortázar
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!